Stephen Cunningham

Direktor/Vorstandsmitglied bei Engrail Therapeutics, Inc.

Health Technology

Profil

Stephen Cunningham is currently the Director & Chief Development Officer at Engrail Therapeutics, Inc. He previously worked as a Director at Chase Pharmaceuticals Corp.

Aktive Positionen von Stephen Cunningham

Unternehmen	Position	Beginn
Engrail Therapeutics, Inc. Engrail Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engrail Therapeutics, Inc. acquires, develops and commercialize transformative medicines. The company was founded in 2019 and is headquartered in San Diego, CA.	Direktor/Vorstandsmitglied	-

Alle aktiven Positionen von Stephen Cunningham

Ehemalige bekannte Positionen von Stephen Cunningham

Unternehmen	Position	Ende
Chase Pharmaceuticals Corp. Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC.	Direktor/Vorstandsmitglied	-

Sehen Sie sich die Erfahrung von Stephen Cunningham im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Stephen Cunningham im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	2
Chase Pharmaceuticals Corp. Chase Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Chase Pharmaceuticals Corp. develops novel medications for the treatment of Alzheimer’s disease. It focuses on pharmaceuticals for Alzheimer type dementia, which include oral medications such as its lead product, CPC-201, as well as CPC 252 for transdermal administration. The company was founded by Thomas N. Chase and Kathleen Clarence-Smith in 2007 and is headquartered in Washington, DC.	Health Technology
Engrail Therapeutics, Inc. Engrail Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engrail Therapeutics, Inc. acquires, develops and commercialize transformative medicines. The company was founded in 2019 and is headquartered in San Diego, CA.	Health Technology